Investigating a new treatment for brain injuries caused by bleeding in the brain.
Official title: BEACH: Biomarker and Edema Attenuation in IntraCerebral Hemorrhage Phase 2a Trial
Funded at Johns Hopkins University · NIH-10997367 · Data updated 2026-11-12
This study is looking at how a new medication called MW189 can help people who have had serious brain injuries from bleeding in the brain, by reducing inflammation and hopefully helping them recover better.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Johns Hopkins University NIH-funded |
| Lab location | 1 site (Baltimore, United States) |
| Project start | February 15, 2021 |
| Project end | November 30, 2025 |
| Funding year | 2025 |
| Award (this year) | $1,244,043 |
| NIH project number | 5R01AG069930-05 |
| Project ID | NIH-10997367 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are adults over 21 who have experienced an acute brain injury, specifically intracerebral hemorrhage.
✕Less likely to help
Patients with chronic brain injuries or those not experiencing acute symptoms may not benefit from this research.
What this research studies
This research focuses on patients who have suffered from acute brain injuries, particularly those caused by intracerebral hemorrhage (ICH). It aims to evaluate the safety and effectiveness of a new medication, MW189, which targets inflammation in the brain that can worsen damage after such injuries. By reducing harmful inflammatory responses, the study hopes to improve recovery outcomes for patients. Participants will be monitored closely to assess the impact of the treatment on their neurological health.
Why it matters
Potential benefit: If successful, this research could lead to improved recovery and reduced complications for patients with acute brain injuries.
How similar studies have gone: Previous research has shown promise in targeting inflammation for improving outcomes in brain injury, making this approach both relevant and potentially impactful.
Where this research is happening
-
Johns Hopkins University
Baltimore, United States Active
Researchers
- Principal investigator: Hanley, Daniel F — Johns Hopkins University
- Study coordinator: Hanley, Daniel F
Related research
Other NIH-funded projects on the same topics.
-
Anticoagulation in ICH Survivors with Atrial Fibrillation and Small Vessel Disease
This project looks at how to safely use blood-thinning medicines in people who survived a brain bleed and also have atrial fibrillation and small vessel disease.
-
Statin use after lobar intracerebral hemorrhage
This trial compares continuing versus stopping statins in people who had a lobar intracerebral hemorrhage to see how that affects repeat brain bleeds, strokes, heart attacks, and recovery over two years.
-
Statin use after lobar brain hemorrhage
This trial compares stopping versus continuing statin medicine in people who had a lobar brain bleed to learn effects on repeat bleeding and future heart or stroke events.
-
Blocking red blood cell death after brain hemorrhage
A study at Yale is exploring whether stopping a specific kind of red blood cell death after a brain hemorrhage could improve recovery.
-
Targeting HDAC3 to reduce brain damage after a brain bleed
This project will test whether blocking a protein called HDAC3 can reduce inflammation and improve recovery after an intracerebral hemorrhage (brain bleed).
-
Silent brain injuries after brain bleed may predict dementia risk
A study using MRI and cognitive tests to see if hidden brain injuries after spontaneous intracerebral hemorrhage help forecast later cognitive decline.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.